Cell Engineering Laboratory, La Paz University Hospital Health Research Institute, IDiPAZ, 28046 Madrid, Spain.
Department of Plastic and Reconstructive Surgery, Santa Cristina Hospital and Centrocim, 28009 Madrid, Spain.
Int J Mol Sci. 2021 Nov 5;22(21):11982. doi: 10.3390/ijms222111982.
Corneal disease affects 12.5 million individuals worldwide, with 2 million new cases each year. The standard treatment consists of a corneal transplantation from a human donor; however, the worldwide demand significantly exceeds the available supply. Lamellar endothelial keratoplasty, the replacement of only the endothelial layer of the cornea, can partially solve the problem. Progressive efforts have succeeded in expanding hCECs; however, the ability to expand hCECs is still limited, and new sources of CECs are being sought. Crucial advances have been achieved by the directed differentiation of embryonic or induced pluripotent stem cells, but these cells have disadvantages, such as the use of oncogenes, and are still difficult to establish. We aimed to transfer such knowledge to obtain hCECs from adipose tissue-derived adult mesenchymal stem cells (ADSC) by modifying four previously published procedures. We present several protocols capable of the directed differentiation of human ADSCs to hCECs. In our hands, the protocol by Ali et al. was the best adapted to such differentiation in terms of efficiency, time, and financial cost; however, the protocol by Wagoner et al. was the best for CEC marker expression. Our results broaden the type of cells of autologous extraocular origin that could be employed in the clinical setting for corneal endothelial deficiency.
角膜疾病影响全球 1250 万人,每年新增病例 200 万。标准治疗方法是从人类供体进行角膜移植;然而,全球需求远远超过了供应。板层内皮角膜移植术,即仅替换角膜的内皮层,可以部分解决这个问题。不断努力成功地扩大了 hCEC 的数量;然而,hCEC 的扩增能力仍然有限,正在寻找新的 CEC 来源。通过定向分化胚胎或诱导多能干细胞已经取得了关键进展,但这些细胞存在使用致癌基因等缺点,并且仍然难以建立。我们旨在将这些知识应用于从脂肪组织来源的成人间充质干细胞(ADSC)中获得 hCEC,方法是修改四个之前发表的程序。我们提出了几个能够将人 ADSC 定向分化为 hCEC 的方案。在我们的实验中,Ali 等人的方案在效率、时间和经济成本方面最适合这种分化;然而,Wagoner 等人的方案最适合 CEC 标志物的表达。我们的结果拓宽了同种异体眼外源性细胞的类型,这些细胞可在临床环境中用于治疗角膜内皮功能不全。